(444 days)
Not Found
No
The description focuses on traditional image processing, coordinate calculations, and trajectory planning based on user input, without mentioning AI or ML algorithms.
No
Explanation: A therapeutic device is one that treats a disease or condition. This device is a software tool used for planning surgical procedures, not for administering treatment itself. The output of the software is a "printed stereotactical plan," which is then used by the neurosurgeon to "administer treatments after review and approval." This indicates it's a planning tool, not a therapeutic device.
No
Explanation: The device is described as software used for planning stereotactic surgeries, specifically for selecting optimal trajectories and calculating device settings. This is a planning and guidance tool, not a device that diagnoses a condition or disease.
Yes
The device description explicitly states "Praezis Plus is a software tool" and details its functions as software-based planning and calculation. There is no mention of accompanying hardware components included with the device itself.
No, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostics are devices intended for use in the collection, preparation, and examination of specimens taken from the human body (such as blood, urine, tissue) to provide information for the diagnosis, treatment, or prevention of disease.
- Praezis Plus Function: The Praezis Plus system is a software tool used for planning intracranial stereotactic surgeries. It processes medical images (CT, MRI, angiographic) to help a neurosurgeon determine the optimal trajectory for a surgical procedure. It does not analyze biological specimens from the patient's body.
- Intended Use: The intended use clearly states it's for "planning intracranial stereotactic surgeries" and the intended user is a "medical doctor - neurosurgeon." This aligns with surgical planning, not in vitro diagnostic testing.
The device is a medical device used in the planning phase of a surgical procedure, not a diagnostic test performed on patient samples.
N/A
Intended Use / Indications for Use
The Praezis Plus system is computer software intended to be used in planning intracranial stereotactic surgeries such as biopsies and treatment of lesions. The intended user of Praezis Plus is a medical doctor - neurosurgeon.
Product codes (comma separated list FDA assigned to the subject device)
HAW
Device Description
Praezis Plus is a software tool intended to help the surgeon plan stereotactic treatments. It enables the user to select optimally fitting stereotactic trajectory positions by digitizing the entry (trephination) and target points of the trajectory. If both points define a trajectory which can be set on the operating device, the corresponding device settings are calculated and displayed in the trajectory window. Any trajectory can be defined and displayed in CT and/or MRI slices or reconstructions or angiographic images if they are available. Trajectories are always stored in stereotactic coordinates and can be digitized and displayed in available patient's modalities (CT, MR or Angiographic). The software can project the selected trajectory to any slices or sections and generate surgeon's eye views. For any possible needle position, the angle settings for either the Riechert/Mundinger (RM) or Zamorano/Dujovny (ZD) stereotactic operating devices can be displayed. Praezis Plus supports the transfer of stereotactic coordinates between angiographic, CT and MR images. Regions of Interest ("ROIs") and Volumes of Interest ("VOIs") can be defined, transferred and displayed between angiographic, CT and MR images. Their area and volume can be calculated. Global stereotactical transformation is available to improve the planning. Image fusion, based on various methods of correlation, allows a combination of valuable information from different modalities. Several types of reconstructed sections such as arbitrary, along and perpendicular to trajectory together with 3D reconstructions are also available. It is possible to print out all the images and protocols and together with patient data archive them on a CD. The output from Praezis Plus is a printed stereotactical plan defining the trajectory and the setup of the stereotactical device. The treatment plans may be used to administer treatments after review and approval by the neurosurgeon.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
CT and/or MRI slices or reconstructions or angiographic images
Anatomical Site
intracranial
Indicated Patient Age Range
Not Found
Intended User / Care Setting
medical doctor - neurosurgeon
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
System Validation: The system validation of Praezis Plus was performed by manufacturer during the validation phase. The relevant features of the pre-released product were tested according to the test plan (a set of test cases) using the test data and the results were recorded to the validation protocol. Some of the tests were designed as benchmark tests to compare validated system to the benchmark system. All the reference values were measured digitally using the benchmark software (Stereoplan Plus), therefore the reference values were considered to be ideally exact. The measured values were taken the same way; therefore absolute equality would be expected. The allowed inaccuracy was enabled only to accept possible cumulative error resulting from limited resolution of imaging and pointing devices. If no tolerance was allowed then only exactly equal results were allowed. These benchmark test results demonstrate that the computation accuracy of Praezis Plus is as good as Stereoplan Plus. The test results support the safe and effective use of the Praezis Plus to guide a device to a brain target with an error less than 1mm.
Beta Site Testing: The beta site testing of Praezis Plus was conducted at two hospitals: 1) Beth Israel Deaconess Medical Center - Harvard Medical School, Boston and 2) University of Chicago Medical Center - Section Of Neurosurgery, Chicago. The basic concept of the beta site testing method was to compare the currently validating version of the product with the bench mark device (Stereoplan Plus) in the near-clinic (virtual) environment. It means all the existing relevant procedures in the hospital were followed in addition to using the features of Praezis Plus software. Thus, the product was not used for reference during the making a diagnosis - it was used in parallel path for result comparison only. The conclusion of the both testing was that Praezis Plus fulfills the declared requirements and is consistently safe and accurate comparing to the bench mark device, thus suitable for use in the scope of its declared intended use.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 882.4560 Stereotaxic instrument.
(a)
Identification. A stereotaxic instrument is a device consisting of a rigid frame with a calibrated guide mechanism for precisely positioning probes or other devices within a patient's brain, spinal cord, or other part of the nervous system.(b)
Classification. Class II (performance standards).
0
K110644
9127
Section 5 - 510(k) Summary
This summary of 510(k) safety and effectiveness information is being submitted in MAY 2 4 2012 accordance with the requirements of 21 CFR §807.92.
Submitter's Name, Address, Telephone Number, Contact Person and Date Prepared
TATRAMED spol. s r.o. Líščie údolie 7, 84104 Bratislava, Slovak republic +421-2-60202301 Tel: Fax: +421-2-60202351
Date Summary Prepared: October 28, 2011
| Contact Person: | Jan Hanzel, Dipl.Ing. |
|---|---|
| e-mail: | jan.hanzel@tatramed.sk |
| Tel: | +421-2-60202329, +421-2-6020230 |
| Fax: | +421-2-60202351 |
Name of Device:
Trade Name(s): Praezis Plus 3.1 Classification Name: Planning system/Stereotaxic instrument Classification: 21 C.F.R §882.4560 Panel: Neurological Product Code: HAW
Predicate Device:
Leibinger Stereoplan Plus Stereotactic Treatment Planning Software Package, Leibinger LP (K946033)
Intended Use/Indications for Use
The Praezis Plus system is computer software intended to be used in planning intracranial stereotactic surgeries such as biopsies and treatment of lesions. The intended user of Praezis Plus is a medical doctor - neurosurgeon.
Technological Characteristics
Praezis Plus is a software tool intended to help the surgeon plan stereotactic treatments. It enables the user to select optimally fitting stereotactic trajectory positions by digitizing the entry (trephination) and target points of the trajectory. If both points define
1
KII 06444
a trajectory which can be set on the operating device, the corresponding device settings are calculated and displayed in the trajectory window. Any trajectory can be defined and displaved in CT and/or MRI slices or reconstructions or angiographic images if they are available. Trajectories are always stored in stereotactic coordinates and can be digitized and displayed in available patient's modalities (CT, MR or Angiographic). The software can project the selected trajectory to any slices or sections and generate surgeon's eye views. For any possible needle position, the angle settings for either the
Riechert/Mundinger (RM) or Zamorano/Dujovny (ZD) stereotactic operating devices can be displayed.
Praezis Plus supports the transfer of stereotactic coordinates between angiographic, CT and MR images. Regions of Interest ("ROIs") and Volumes of Interest ("VOIs") can be defined, transferred and displayed between angiographic, CT and MR images. Their area and volume can be calculated.
Global stereotactical transformation is available to improve the planning. Image fusion, based on various methods of correlation, allows a combination of valuable information from different modalities. Several types of reconstructed sections such as arbitrary, along and perpendicular to trajectory together with 3D reconstructions are also available. It is possible to print out all the images and protocols and together with patient data archive them on a CD.
The output from Praezis Plus is a printed stereotactical plan defining the trajectory and the setup of the stereotactical device. The treatment plans may be used to administer treatments after review and approval by the neurosurgeon.
See the table below for a detailed comparison of the technological characteristics of Praezis Plus and the predicate device.
2
| Characteristic | Praezis Plus | Stereoplan Plus (K946033) |
|---|---|---|
| Product Code | ||
| Classification Regulation | ||
| Indication for Use | 21 CFR 882.4560 | |
| The Praezis Plus system is computer software intended to be used in planning intracranial stereotactic surgeries such as biopsies and treatment of lesions. The intended user of Praezis Plus is a medical doctor - neurosurgeon. | HAW | |
| 21 CFR 882.4560 | ||
| The Stereoplan Plus is intended to be used in planning stereotactic treatment of intracerebral lesions. | ||
| Specifically, the Stereoplan Plus system is intended for planning stereotactic punctures. This indication for use is cleared for the predicate device the STP Complete Module Set, also developed and marketed by Leibinger under K892425/D. | ||
| Brief Device Description | Praezis Plus is a software tool intended to help the surgeon plan stereotactic treatments. It enables the user to select optimally fitting stereotactic trajectory positions by digitizing the entry (trephination) and target points of the trajectory. If both points define a trajectory which can be set on the operating device, the corresponding device settings are calculated and displayed in the trajectory window. Any trajectory can be defined and displayed in CT and/or MRI slices or reconstructions or angiographic images if they are available. Trajectories are always stored in stereotactic coordinates and can be digitized and displayed in available patient's modalities (CT, MR or Angiographic). The software can project the selected trajectory to any slices or sections and generate surgeon's eye views. For any possible needle position, the angle settings for either the Riechert/Mundinger (RM) or Zamorano/Dujovny (ZD) stereotactic operating devices can be displayed. | Stereoplan Plus is a software tool intended to help the surgeon plan stereotactic treatments. It enables the user to select optimally fitting stereotactic catheter positions by digitizing the entry (trephination) and target points of the catheter needle. If both points define a needle which can be set on the operating device, the corresponding angles are calculated and displayed in the needle window. Any needle can be defined and displayed in CT slices or sections or angiographic images if they are available. Needles are always stored in stereotactic coordinates and can be digitized and displayed in any space of patient's images (CT, MR or Angiographic). The software can project the selected needle to any slices or sections and generate surgeon's eye views. For any possible needle position, the angle settings for either the Riechert/Mundinger or Zamorano/Dujovny stereotactic operating devices can be displayed. |
| Stereoplan Plus supports the transfer of stereotactic | ||
| Characteristic | Praezis Plus | Stereoplan Plus (K946033) |
| Praezis Plus supports the transfer of stereotactic | ||
| coordinates between angiographic, CT and MR images. | ||
| Regions of Interest ("ROIs") and Volumes of Interest | ||
| ("VOIs") can be defined, transferred and displayed | ||
| between angiographic, CT and MR images. Their area | ||
| and volume can be calculated. | ||
| Global stereotactical transformation is available to | ||
| improve the planning. Image fusion, based on various | ||
| methods of correlation, allows a combination of | ||
| valuable information from different modalities. Several | ||
| types of reconstructed sections such as arbitrary, along | ||
| and perpendicular to trajectory together with 3D | ||
| reconstructions are also available. | ||
| It is possible to print out all the images and protocols | ||
| and together with patient data archive them on a CD. | ||
| The output from Praezis Plus is a printed stereotactical | ||
| plan defining the trajectory and the setup of the | ||
| stereotactical device. The treatment plans may be used | ||
| to administer treatments after review and approval by | ||
| the neurosurgeon. | coordinates between angiographic, CT and MR images. | |
| Regions of Interest ("ROIs") and Volumes of Interest | ||
| ("VOIs") can be defined, transferred and displayed | ||
| between angiographic, CT and MR images. Their area | ||
| and volume can be calculated. | ||
| There are two major components of the Stereoplan Plus | ||
| System: the hardware utilized to position and restraint | ||
| the patient's head; and the software used to position the | ||
| hardware. | ||
| Intended User | Neurosurgeon | Neurosurgeon |
| Operating principle | Stereotactic planning software | Stereotactic planning software |
| Stand alone software | ||
| application | Yes | Yes |
| Characteristic | ||
| Software features | Praezis Plus | Stereoplan Plus (K946033) |
| DICOM image loading | DICOM image loading | |
| Image presentation | Image presentation | |
| Stereotactical image registration | Stereotactical image registration | |
| Multimodal registration | Identity based Multimodal registration on the stereotactical ring | |
| Automatic multimodal registration | Atlas registration | |
| Atlas registration | Image reconstructions | |
| Image reconstructions | 3D reconstructions | |
| Image fusion | Contouring the patient – create ROIs | |
| 3D reconstructions | Trajectory planning | |
| Contouring the patient - create ROIs | Trajectory planning functional | |
| Trajectory planning | Stereotactical device calculation | |
| Trajectory planning functional | Print images | |
| Stereotactical device calculation | Registrations archived in private groups of DICOM files | |
| Print images | ||
| Registrations archived in private groups of DICOM files | ||
| Image reslicing | ||
| DICOM export |
KII 0644
R.3277
3
次川市644
4
人110644
5
p.687
Consensus Standards
Praezis Plus complies with the following recognized consensus standards:
- ISO 14971:2007 Medical devices Application of risk management to medical . devices (FDA Recognition number 5-40)
- NEMA PS 3.1-3.18 2008 Digital Imaging and Communications in Medicine . (DICOM) (FDA Recognition number 12-183 )
- EN 62304 EN 62304:2006 Medical device software Software life cycle . processes (FDA Recognition number 13-8 )
Performance Data
System Validation
The system validation of Praezis Plus was performed by manufacturer during the validation phase. The relevant features of the pre-released product were tested according to the test plan (a set of test cases) using the test data and the results were recorded to the validation protocol.
Some of the tests were designed as benchmark tests to compare validated system to the benchmark system. All the reference values were measured digitally using the benchmark software (Stereoplan Plus), therefore the reference values were considered to be ideally exact. The measured values were taken the same way; therefore absolute equality would be expected. The allowed inaccuracy was enabled only to accept possible cumulative error resulting from limited resolution of imaging and pointing devices. If no tolerance was allowed then only exactly equal results were allowed.
These benchmark test results demonstrate that the computation accuracy of Praezis Plus is as good as Stereoplan Plus. The test results support the safe and effective use of the Praezis Plus to guide a device to a brain target with an error less than Imm.
Beta Site Testing
The beta site testing of Praezis Plus was conducted at two hospitals:
-
Beth Israel Deaconess Medical Center - Harvard Medical School, Boston and
-
University of Chicago Medical Center - Section Of Neurosurgery, Chicago.
The basic concept of the beta site testing method was to compare the currently validating version of the product with the bench mark device (Stereoplan Plus) in the near-clinic (virtual) environment. It means all the existing relevant procedures in the hospital were followed in addition to using the features of Praezis Plus software. Thus, the product was not used for reference during the making a diagnosis - it was used in parallel path for result comparison only.
The conclusion of the both testing was that Praezis Plus fulfills the declared requirements and is consistently safe and accurate comparing to the bench mark device, thus suitable for use in the scope of its declared intended use.
6
Substantial Equivalence
110644
p.737
Praezis Plus and its predicate device are stand-alone software systems that are equivalent in indications for use and technology.
Praezis Plus supports all of the features of the Stereoplan Plus (including DICOM image loading, image presentation, reconstruction contouring, 3D reconstruction, stereotactical images, and atlas registration; trajectory planning, and stereotactical device calculation). Moreover, Praezis Plus supports automatic multimodal registration and image fusion; image reslicing, and DICOM export.
Praezis Plus is as safe and effective as the Stereoplan Plus. Praezis Plus has the same intended use and similar indications, technological characteristics. The minor technological differences between Praezis Plus and its predicate device raise no new issues of safety or effectiveness. Performance data demonstrate Praezis Plus is as safe and effective as the predicate device. Thus, Praezis Plus is substantially equivalent.
7
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/7/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized caduceus symbol, which features a staff entwined with a serpent, and is accompanied by the text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" arranged in a circular fashion around the symbol. The caduceus is depicted with three wing-like shapes above the staff and serpent.
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002
TatraMed spol. s.r.o. c/o Ms. Caroline Tontini Project Manager Emergo Group 611 W. 5th St., Third Floor Austin, TX 78701
Re: K110644
Trade/Device Name: Praezis Plus Regulation Number: 21 CFR 882.4560 Regulation Name: Stereotaxic Instrument Regulatory Class: Class II Product Code: HAW Dated: May 21, 2012 Received: May 22, 2012
MAY 2 4 2012
Dear Ms. Tontini:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
8
Page 2 - Ms. Caroline Tontini
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH0ffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
http://www.fda.gov/MedicalDevices/ResourcestoYou/Industry/default.htm.
Sincerely yours,
Melvin R. Felder, MD
Malvina B. Eydelman, M, Director Division of Ophthalmic, Neurological, and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
9
Indications for Use
510(k) Number (if known): K110644
Device Name: Praezis Plus
Indications for Use:
The Praezis Plus system is computer software intended to be used in planning intracranial stereotactic surgeries such as biopsies and treatment of lesions. The intended user of Praezis Plus is a medical doctor - neurosurgeon.
Prescription Use XX (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
John Zineit
(Division Sign-Off) Division of Ophthalmic, Neurological and Ear, Nose and Throat Devices
510(k) Number K110644
Prescription Use
(Per 21 CFR 801.109)